Author(s): Hoffman LK, Ghias M, Cohen SR, Lowes MA
Hidradenitis suppurativa (HS) is a chronic, painful inflammatory skin disease characterized by recurrent nodules and abscesses affecting intertriginous areas including the axilla, inframammary, and anogenital regions. Hurley staging (I-III) is commonly used to classify patients, with mild disease limited to inflammatory cystic nodules (stage I), that may be connected by isolated tunnels/sinuses (stage II), or form a network of bridging tunnels/sinuses (stage III) associated with odiferous, purulent drainage. The cause of HS is unknown but it is generally considered to be multifactorial. It appears that an aberrant innate immune response initiates cutaneous inflammation in early lesions and recruitment of the adaptive immune system may be involved in maintaining HS chronicity.(1) Only a few published studies have focused on the humoral immune system in HS. The sera of patients with advanced HS revealed elevations of tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IgE.(2-4) Significantly increased levels of C-reactive protein (CRP) have been found across all three Hurley stages.(5) This article is protected by copyright. All rights reserved.
Dermatology Journal and/or Publisher
Journal Name: The British journal of dermatology
Journal Abbreviation: Br. J. Dermatol.
Journal Date Published: 2017-09-08
National Center for Biotechnology Information
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/28886222
Lasted Revision: 2017-09-08
Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).
Tags: Inflammatory Treatment